NASDAQ:ENTA Enanta Pharmaceuticals (ENTA) Stock Price, News & Analysis $7.34 -0.39 (-5.05%) Closing price 04:00 PM EasternExtended Trading$7.34 +0.00 (+0.01%) As of 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Enanta Pharmaceuticals Stock (NASDAQ:ENTA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Enanta Pharmaceuticals alerts:Sign Up Key Stats Today's Range$7.33▼$7.7550-Day Range$5.37▼$7.9752-Week Range$4.09▼$15.92Volume93,488 shsAverage Volume297,555 shsMarket Capitalization$156.93 millionP/E RatioN/ADividend YieldN/APrice Target$18.00Consensus RatingModerate Buy Company Overview Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts. Read More Enanta Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks78th Percentile Overall ScoreENTA MarketRank™: Enanta Pharmaceuticals scored higher than 78% of companies evaluated by MarketBeat, and ranked 206th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingEnanta Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageEnanta Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Enanta Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Enanta Pharmaceuticals are expected to decrease in the coming year, from ($4.65) to ($4.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enanta Pharmaceuticals is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enanta Pharmaceuticals is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnanta Pharmaceuticals has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Enanta Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.19% of the float of Enanta Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEnanta Pharmaceuticals has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.Change versus previous monthShort interest in Enanta Pharmaceuticals has recently decreased by 3.20%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnanta Pharmaceuticals does not currently pay a dividend.Dividend GrowthEnanta Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-1.11 Percentage of Shares Shorted12.19% of the float of Enanta Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEnanta Pharmaceuticals has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.Change versus previous monthShort interest in Enanta Pharmaceuticals has recently decreased by 3.20%, indicating that investor sentiment is improving. News and Social Media2.8 / 5News SentimentN/A News SentimentEnanta Pharmaceuticals has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Enanta Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest1 people have searched for ENTA on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Enanta Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Enanta Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders13.89% of the stock of Enanta Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.99% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enanta Pharmaceuticals' insider trading history. Receive ENTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ENTA Stock News HeadlinesEnanta Pharmaceuticals to Participate in Baird’s Biotech Discovery SeriesJuly 16, 2025 | finance.yahoo.comEnanta Pharmaceuticals to Participate in Baird's Biotech Discovery SeriesJuly 15, 2025 | businesswire.comElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regain control, one overlooked IRS “backdoor” still allows retirement savers to protect their wealth — penalty-free and tax-free. A free 2025 guide reveals how to use it before it’s too late.July 24 at 2:00 AM | Priority Gold (Ad)Enanta Pharmaceuticals, Inc. (ENTA) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comFDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED)June 11, 2025 | finance.yahoo.comEnanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C VirusJune 11, 2025 | businesswire.comEnanta Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceMay 27, 2025 | finance.yahoo.comEnanta Pharmaceuticals, Inc.: Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the ...May 24, 2025 | finanznachrichten.deSee More Headlines ENTA Stock Analysis - Frequently Asked Questions How have ENTA shares performed this year? Enanta Pharmaceuticals' stock was trading at $5.75 at the start of the year. Since then, ENTA stock has increased by 29.2% and is now trading at $7.43. How were Enanta Pharmaceuticals' earnings last quarter? Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) issued its quarterly earnings results on Monday, May, 12th. The biotechnology company reported ($1.06) earnings per share for the quarter, missing analysts' consensus estimates of ($1.04) by $0.02. The biotechnology company had revenue of $14.93 million for the quarter, compared to the consensus estimate of $15.96 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 79.83% and a negative net margin of 149.57%. Who are Enanta Pharmaceuticals' major shareholders? Enanta Pharmaceuticals' top institutional shareholders include Assenagon Asset Management S.A. (0.50%), Public Employees Retirement System of Ohio (0.06%), Wealth Enhancement Advisory Services LLC (0.05%) and Farther Finance Advisors LLC (0.03%). Insiders that own company stock include Jay R Luly, Yat Sun Or, Paul J Mellett, Brendan Luu, Tara Lynn Kieffer, Scott T Rottinghaus and Terry Vance. View institutional ownership trends. How do I buy shares of Enanta Pharmaceuticals? Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enanta Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enanta Pharmaceuticals investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD) and Alphabet (GOOG). Company Calendar Last Earnings5/12/2025Today7/24/2025Next Earnings (Estimated)8/04/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ENTA CIK1177648 Webwww.enanta.com Phone(617) 607-0800Fax617-607-0530Employees160Year FoundedN/APrice Target and Rating Average Price Target for Enanta Pharmaceuticals$18.00 High Price Target$24.00 Low Price Target$10.00 Potential Upside/Downside+145.2%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($4.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$116.04 million Net Margins-149.57% Pretax Margin-153.41% Return on Equity-79.83% Return on Assets-26.65% Debt Debt-to-Equity RatioN/A Current Ratio5.29 Quick Ratio5.29 Sales & Book Value Annual Sales$67.64 million Price / Sales2.32 Cash FlowN/A Price / Cash FlowN/A Book Value$6.08 per share Price / Book1.21Miscellaneous Outstanding Shares21,380,000Free Float18,408,000Market Cap$156.93 million OptionableOptionable Beta0.84 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:ENTA) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.